Copyright © 2006, European Society of Cardiology
The ubiquitin–proteasome system: Focus on the heart
Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University Erlangen-Nuremberg, Germany
* Corresponding author. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstr. 17, 91054 Erlangen, Germany. Tel.: +49 9131 8522783; fax: +49 9131 8522773. Email address: Zolk{at}pharmakologie.uni-erlangen.de
Proteasomes are the main non-lysosomal multicatalytic protease complexes that are involved in the degradation of most intracellular proteins. The substrate proteins are marked by ubiquitin, which serves as a tag for their regulated proteasomal destruction. One major function of the ubiquitin–proteasome system (UPS) is to prevent accumulation of non-functional, potentially toxic proteins. Moreover, it has become clear that the UPS is involved in most aspects of eukaryotic biology, such as intracellular signaling, transcriptional control, or regulation of cell death. Recent studies demonstrated that the UPS regulates receptor internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in cardiomyocytes. Since structural remodeling of the myocardium, ischemia–reperfusion injury, and myocardial cell loss are important components in the genesis of progressive heart failure, these findings suggest a pathophysiological role of the UPS. This review briefly summarizes present knowledge about structure and function of the proteasome in the heart and discusses the relevance of the UPS for cardiac diseases.
KEYWORDS Cardiomyopathy; Heart failure; Ischemia–reperfusion; Proteasome; Proteasome inhibitor; Ubiquitin
Time for primary review 27 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Tsukamoto, T. Minamino, and M. Kitakaze Functional alterations of cardiac proteasomes under physiological and pathological conditions Cardiovasc Res, September 4, 2009; (2009) cvp282v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Carrier, S. Schlossarek, M. S. Willis, and T. Eschenhagen Ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy Cardiovasc Res, August 10, 2009; (2009) cvp247v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Haimerl, A. Erhardt, G. Sass, and G. Tiegs Down-regulation of the De-ubiquitinating Enzyme Ubiquitin-specific Protease 2 Contributes to Tumor Necrosis Factor-{alpha}-induced Hepatocyte Survival J. Biol. Chem., January 2, 2009; 284(1): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hedhli, L. Wang, Q. Wang, E. Rashed, Y. Tian, X. Sui, K. Madura, and C. Depre Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22 Cardiovasc Res, February 1, 2008; 77(3): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Shenoy Seven-Transmembrane Receptors and Ubiquitination Circ. Res., April 27, 2007; 100(8): 1142 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth Readers' choice: Hot papers downloaded in 2006 Cardiovasc Res, March 1, 2007; 73(4): 619 - 622. [Full Text] [PDF]
|
|